Last updated: April 25, 2026
Who Supplies Mometasone Furoate and Olopatadine Hydrochloride?
This report maps the pharmaceutical supply base for mometasone furoate and olopatadine hydrochloride across API manufacturers and formulation/finished-dose suppliers. It focuses on companies that are repeatedly active in global supply chains for these drug substances and their common dosage forms (nasal, ophthalmic, oral, topical).
Mometasone Furoate: Who supplies the API and finished products?
API supply (mometasone furoate)
The core global API supply base for metered-dose and nasal applications is typically concentrated in a set of established CMO/API producers with broad steroids capability. Active suppliers include:
| Supplier |
Primary role in supply chain |
Typical end-market relevance |
| Siegfried (including through steroid/anti-infective capabilities) |
API and advanced intermediates |
Global branded and generic nasal/ocular steroid products |
| Bachem (mometasone-related steroid chemistry capability) |
Intermediates and contract manufacturing |
Steroid API supply continuity and scale-up support |
| CordenPharma (contract manufacturing network) |
CMO for steroid solids and scale-up |
API and finished-dose support via CDMO projects |
| Hetero (API manufacturing network) |
Generic API supply |
Branded generic portfolios, including ENT use cases |
| Sun Pharma (API/CRAMS in steroid classes) |
API supply and manufacturing scale |
Broad generic penetration, including nasal formulations |
| Dr. Reddy’s (API manufacturing network) |
API supply |
Global markets for steroid ENT indications |
| Lupin (API manufacturing network) |
API supply |
Generic pipeline and product manufacturing support |
| Teva/Teva affiliates (manufacturing footprint) |
API and finished product supply |
Large-scale generic and branded supply |
Finished product supply (common forms)
Mometasone furoate is used in nasal sprays and topical formulations. In many markets, finished-dose supply is held by branded originators and multi-source generics. Common supplier groups include:
- Market-leading branded portfolio holders (brand owners and/or their manufacturers)
- Global generics manufacturers with ENT and dermatology franchise manufacturing sites, including Sandoz, Teva, Mylan/Viatris, Dr. Reddy’s, Lupin, and Sun Pharma.
Olopatadine Hydrochloride: Who supplies the API and finished products?
API supply (olopatadine hydrochloride)
Olopatadine is primarily supplied for ophthalmic products (solution/drops) and, in some markets, extended-release oral formats. API sourcing is concentrated among developers and generic manufacturers with strong heterocycle and ophthalmic formulation experience. Active suppliers include:
| Supplier |
Primary role in supply chain |
Typical end-market relevance |
| Siegfried (API/CDMO steroid and ophthalmic-adjacent capability) |
API/CDMO |
Manufacturing scale and tech transfer support |
| CordenPharma |
CDMO/APIs |
Ophthalmic and solid oral platform support |
| Hetero |
API supply |
Broad generic coverage including ophthalmic actives |
| Sun Pharma |
API supply |
Ophthalmic generic portfolios |
| Dr. Reddy’s |
API supply |
Generic pipeline across eye care |
| Lupin |
API supply |
Ophthalmic dosage forms supply |
| Mylan/Viatris |
finished dose supply via manufacturing networks |
Ocular franchise manufacturing |
| Sandoz |
finished dose supply via manufacturing networks |
Ocular generic supply to multiple geographies |
Finished product supply (common forms)
Olopatadine is most widely sold as ophthalmic drops (often 0.1% or 0.2% in various region-specific standards). Finished-dose supply commonly comes from:
- Ophthalmic-focused generic manufacturers and large generics groups with ophthalmic product lines (examples in the global market include Alcon’s ecosystem via distribution, and large generics suppliers such as Sandoz, Teva, Viatris, Dr. Reddy’s, Lupin, Sun Pharma).
- Local MAH and parallel importers in specific jurisdictions, which purchase finished product or relabeled stock from the same manufacturing base.
How these supplier sets typically map to business sourcing decisions
1) If you need API-only supply
- Use the API manufacturers above for direct supply programs.
- Validate with your compliance workflow on CoA, particle specs, polymorph control, and residual solvent targets.
2) If you need finished-dose manufacturing
- Use large generics manufacturers and CDMOs with proven ophthalmic/ENT sterile or near-sterile lines depending on route.
- Expect more variability in finished-dose lead times than API sourcing due to labeling, packaging, and sterile fill/finish capacity.
3) If you need both drugs under one development platform
- CDMOs such as CordenPharma and Siegfried are the more common shared endpoints because they can support both small-molecule APIs and formulation manufacturing programs across different therapeutic categories.
Key Takeaways
- Mometasone furoate supply is dominated by global steroid-experienced API manufacturers and CDMOs plus large-scale ENT topical/nasal generics manufacturing groups.
- Olopatadine hydrochloride supply is dominated by ophthalmic-ready API manufacturers and large generics companies with ocular formulation scale.
- For procurement, the most efficient sourcing is typically split into API-only channels (Siegfried, CordenPharma, and major generic API producers) and finished-dose channels (major global generics and ophthalmic/ENT manufacturing platforms).
FAQs
1) Who are the most common API supplier archetypes for these drugs?
API supply is typically split between global generic API manufacturers (large production networks) and specialist CDMOs/API houses that handle tech transfer and scale-up.
2) Are the same suppliers used for both molting molecule and ophthalmic drugs?
Overlap exists mainly at the CDMO tier, where steroid and heterocycle small molecules can be supported under shared manufacturing governance.
3) What finished-dose manufacturers matter most for ophthalmic olopatadine?
Large generics groups with ocular lines and packaging capacity, plus region-specific MAHs, drive market availability more than smaller API-only players.
4) What is the main procurement risk for finished doses?
The operational bottleneck usually shifts from API to formulation fill-finish capacity, sterile/near-sterile controls, and regulatory release timelines.
5) What strategy works best for dual-asset sourcing?
Use CDMO channels for tech transfer and formulation support and API-only channels for cost and volume, then align release timelines at the finished-dose stage.
References (APA)
[1] FDA Orange Book. (n.d.). Drugs@FDA / Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
[2] EMA. (n.d.). European Medicines Agency medicines database. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] WHO. (n.d.). WHO prequalification programme. World Health Organization. https://extranet.who.int/pqweb/
